Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet
Shufei Zeng, Denis Delić, Chang Chu, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112606-112606
Open Access | Times Cited: 24

Showing 24 citing articles:

Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
Xin Chen, Carl‐Friedrich Hocher, Linghong Shen, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 3, pp. C661-C681
Closed Access | Times Cited: 32
Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system
Xin Chen, Denis Delić, Yaochen Cao, et al.
AJP Cell Physiology (2023) Vol. 324, Iss. 4, pp. C951-C962
Open Access | Times Cited: 31
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events
Buena Aziri, Edin Begić, Slobodan Јаnkovic, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 3, pp. 1499-1530
Open Access | Times Cited: 23
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Ashish Upadhyay
Kidney360 (2024) Vol. 5, Iss. 5, pp. 771-782
Open Access | Times Cited: 9
Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy
Yong-Ping Lu, Hongwei Wu, Ting Zhu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113947-113947
Open Access | Times Cited: 32
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
Francesco Bellanti, Aurelio Lo Buglio, Michał Dobrakowski, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 26, pp. 3243-3257
Open Access | Times Cited: 30
Myocardial Oedema as a Consequence of Viral Infection and Persistence—A Narrative Review with Focus on COVID-19 and Post COVID Sequelae
N Panagiotides, Michael Poledniczek, Martin Andreas, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 121-121
Open Access | Times Cited: 6
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
Arianna Maiorana, Francesco Tagliaferri, Carlo Dionisi‐Vici
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 15
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Jun-Pei Hu, Jianhui Teng, Shan Hui, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29486-e29486
Open Access | Times Cited: 5
Head-to-head comparison of two SGLT-2 inhibitors on AKI outcomes in a rat ischemia-reperfusion model
Chang Chu, Denis Delić, Jana Alber, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113357-113357
Open Access | Times Cited: 22
A comprehensive review of the efficacy and safety of ertugliflozin
Bo Xu, Yilin Liu, Tianqiao Zhang, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
Giovanna Castoldi, Raffaella Carletti, Francesca Barzaghi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 362-362
Open Access | Times Cited: 3
Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet
Silvie Hojná, Hana Malínská, Martina Hüttl, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116520-116520
Open Access | Times Cited: 3
RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor
Fangyan Tan, Xianglin Long, Jianlin Du, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115289-115289
Open Access | Times Cited: 9
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Wei Huang, Yiyuan Chen, Ziqi Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10882-10882
Open Access | Times Cited: 14
Sodium–glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms
Barış Afşar, Rengin Elsürer Afşar
Pharmacological Reports (2022) Vol. 75, Iss. 1, pp. 44-68
Closed Access | Times Cited: 13
Intact Fibroblast Growth Factor 23 Regulates Chronic Kidney Disease–Induced Myocardial Fibrosis by Activating the Sonic Hedgehog Signaling Pathway
Lanlan Li, Hua Gan
Journal of the American Heart Association (2022) Vol. 11, Iss. 18
Open Access | Times Cited: 9
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
Silvie Hojná, Zoe Kotsaridou, Zdeňka Vaňourková, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2509-2509
Open Access | Times Cited: 9
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Ivana Vaněčková, Josef Zicha
Physiological Research (2024), Iss. Suppl 1, pp. S377-S387
Open Access | Times Cited: 1
Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy—effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker
Yingquan Xiong, Denis Delić, Shufei Zeng, et al.
BMC Nephrology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy
M. Hassaan Rehman, Ariba Qaiser, Hassan Sardar Khan, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access
Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: lessons from preclinical studies
Rayla Rodrigues Soares, Larissa Freitas Viggiani, Juliano Moreira Reis Filho, et al.
Chemico-Biological Interactions (2024) Vol. 403, pp. 111229-111229
Closed Access
SGLT-2 Inhibitors as Novel Treatments of Multiple Organ Fibrosis
Jun-Pei Hu, Shan Hui, Jianhui Teng, et al.
(2024)
Closed Access
Simultaneous SGLT2 inhibition and caloric restriction improves insulin resistance and kidney function in OLETF rats
Manuel Alejandro Cornejo, Eira Jardines, Akira Nishiyama, et al.
Molecular and Cellular Endocrinology (2022) Vol. 560, pp. 111811-111811
Open Access | Times Cited: 1
Page 1

Scroll to top